SG11201907196YA - Composition and methods for preventing radiation injury and promoting tissue regeneration - Google Patents

Composition and methods for preventing radiation injury and promoting tissue regeneration

Info

Publication number
SG11201907196YA
SG11201907196YA SG11201907196YA SG11201907196YA SG11201907196YA SG 11201907196Y A SG11201907196Y A SG 11201907196YA SG 11201907196Y A SG11201907196Y A SG 11201907196YA SG 11201907196Y A SG11201907196Y A SG 11201907196YA SG 11201907196Y A SG11201907196Y A SG 11201907196YA
Authority
SG
Singapore
Prior art keywords
international
rule
methods
pct
preventing radiation
Prior art date
Application number
SG11201907196YA
Inventor
Gautam Ghatnekar
Original Assignee
Firststring Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Firststring Research Inc filed Critical Firststring Research Inc
Publication of SG11201907196YA publication Critical patent/SG11201907196YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Abstract

3 a) , (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT IiiimmomitiaonolomoluotioloilionovoimIE (10) International Publication Number WO 2018/151823 Al (51) International Patent Classification: A61K 9/06 (2006.01) A61K 38/17 (2006.01) A61K 38/10 (2006.01) C07K 14/46 (2006.01) (21) International Application Number: PCT/US2018/000035 (22) International Filing Date: 16 February 2018 (16.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/459,924 16 February 2017 (16.02.2017) US (71) Applicant: FIRSTSTRING RESEARCH, INC. [US/US]; 300 West Coleman Boulevard, Suite 203, Mt. Pleasant, SC 29464 (US). (72) Inventor: GHATNEKAR, Gautam; 1064 Oakcrest Drive, Charleston, SC 29412 (US). (74) Agent: TEAGUE, Meghann, K. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC 20004-2400 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) — (54) Title: COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGEN- ERATION 4 Vehicle 3.5 - 'Granexin 100 NM . rt 'Granexin 200 NM r -r, — 0.5 0 00 0 5 10 15 20 Day post irradiation 25 30 Fig. lA 1-1 \" (57) : Provided herein are compositions and methods for use in treating or preventing radiation injury in a subject at risk of C such injury. [Continued on next page] WO 2018/151823 Al MIDEDIM01101 DIOBEIE3111111111111111111111111111111111111111111111111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201907196YA 2017-02-16 2018-02-16 Composition and methods for preventing radiation injury and promoting tissue regeneration SG11201907196YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459924P 2017-02-16 2017-02-16
PCT/US2018/000035 WO2018151823A1 (en) 2017-02-16 2018-02-16 Composition and methods for preventing radiation injury and promoting tissue regeneration

Publications (1)

Publication Number Publication Date
SG11201907196YA true SG11201907196YA (en) 2019-09-27

Family

ID=63170684

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201907196YA SG11201907196YA (en) 2017-02-16 2018-02-16 Composition and methods for preventing radiation injury and promoting tissue regeneration
SG10202107725RA SG10202107725RA (en) 2017-02-16 2018-02-16 Composition and methods for preventing radiation injury and promoting tissue regeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202107725RA SG10202107725RA (en) 2017-02-16 2018-02-16 Composition and methods for preventing radiation injury and promoting tissue regeneration

Country Status (12)

Country Link
US (1) US20230147795A1 (en)
EP (1) EP3582754B1 (en)
JP (1) JP7145163B2 (en)
KR (1) KR20190135470A (en)
CN (1) CN110520108A (en)
AU (1) AU2018221221B2 (en)
BR (1) BR112019017087A2 (en)
CA (1) CA3053096A1 (en)
IL (1) IL268661A (en)
MX (1) MX2019009753A (en)
SG (2) SG11201907196YA (en)
WO (1) WO2018151823A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3085784A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer driver and controller
US20210361741A1 (en) * 2018-09-12 2021-11-25 Firststring Research, Inc. Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
CN110358783A (en) * 2019-06-28 2019-10-22 深圳市容大生物技术有限公司 Recombinant plasmid, recombination engineering and its application
KR20210104319A (en) 2020-02-17 2021-08-25 노태성 Compositions for Treating Diabetic Ulcers
CN114522165A (en) * 2022-01-21 2022-05-24 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Application of sanguinarine chloride in preparation of medicine or health product for treating liver injury caused by arsenic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2006033412A1 (en) * 2004-09-24 2006-03-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Alleviator for radiation disorder
HUE038099T2 (en) * 2004-12-21 2018-09-28 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
CN101151043B (en) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 Composition and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) * 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
CN101631799A (en) * 2006-10-30 2010-01-20 南方研究院 Target NBS1-ATM interact so that cancer cells to radiotherapy and chemotherapy sensitivity
CA2841713A1 (en) * 2011-07-15 2013-01-24 Anthrogenesis Corporation Treatment of radiation injury using amnion derived adherent cells
KR102038948B1 (en) * 2012-03-01 2019-11-26 퍼스트스트링 리서치 인코포레이티드 Topical Gels Containing Alpha Connexin C-Terminal (ACT) Peptides
WO2015123383A1 (en) * 2014-02-12 2015-08-20 Rodgers Kathleen E Methods for promoting wound healing

Also Published As

Publication number Publication date
EP3582754A4 (en) 2020-12-30
AU2018221221B2 (en) 2022-03-24
CA3053096A1 (en) 2018-08-23
JP7145163B2 (en) 2022-09-30
CN110520108A (en) 2019-11-29
KR20190135470A (en) 2019-12-06
JP2020507600A (en) 2020-03-12
US20230147795A1 (en) 2023-05-11
RU2019128841A3 (en) 2021-06-01
RU2019128841A (en) 2021-03-16
SG10202107725RA (en) 2021-09-29
WO2018151823A1 (en) 2018-08-23
EP3582754A1 (en) 2019-12-25
BR112019017087A2 (en) 2020-04-14
IL268661A (en) 2019-10-31
MX2019009753A (en) 2019-12-18
EP3582754B1 (en) 2024-01-10
AU2018221221A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811432WA (en) Rna for cancer therapy
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201901394XA (en) Neisseria meningitidis vaccine
SG11201811580SA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201900543SA (en) Gene therapy for the treatment of aldehyde dehydrogenase deficiency